Search

Sarathi V Boddapati

from Germantown, MD
Age ~47

Sarathi Boddapati Phones & Addresses

  • 20232 Tidewinds Way, Germantown, MD 20874
  • 24 Queensberry St, Boston, MA 02215
  • Dorchester, MA
  • Natick, MA
  • 19254 Circle Gate Dr APT 203, Germantown, MD 20874

Work

Company: Catalent biologics paragon gene therapy Aug 2019 Position: Associate director, formulation and drug product development

Education

Degree: Doctorates, Doctor of Philosophy School / High School: Northeastern University 2001 to 2007

Skills

Formulation • Biotechnology • Vaccines • Pharmaceutical Industry • Technology Transfer • Biopharmaceuticals • Gmp • Glp • Drug Development • Drug Discovery • Drug Delivery • Protein Chemistry • Life Sciences • Validation • Hplc • Cell Culture • Fda • Pharmaceutics • Regulatory Affairs • Sop • Lifesciences • Biochemistry • Purification • Elisa • Chromatography • Cell Biology • Formulation Development • Product Development • Clinical Development • Pharmaceuticals • Pharmaceutical Development

Languages

Hindi • Telugu

Industries

Pharmaceuticals

Resumes

Resumes

Sarathi Boddapati Photo 1

Associate Director, Formulation And Drug Product Development

View page
Location:
Washington, DC
Industry:
Pharmaceuticals
Work:
Catalent Biologics Paragon Gene Therapy
Associate Director, Formulation and Drug Product Development

Novavax
Associate Director, Formulation Development and Product Characterization

Novavax Apr 2015 - Oct 2017
Senior Manager Formulation Development

Novavax Oct 2012 - Apr 2015
Manager Formulations Process Development

Novavax Oct 2009 - Oct 2012
Senior Scientist-Formulation Development
Education:
Northeastern University 2001 - 2007
Doctorates, Doctor of Philosophy
P.g. College of Law, Basheerbagh 1995 - 1999
Bachelors, Bachelor of Pharmacy, Pharmacy
Skills:
Formulation
Biotechnology
Vaccines
Pharmaceutical Industry
Technology Transfer
Biopharmaceuticals
Gmp
Glp
Drug Development
Drug Discovery
Drug Delivery
Protein Chemistry
Life Sciences
Validation
Hplc
Cell Culture
Fda
Pharmaceutics
Regulatory Affairs
Sop
Lifesciences
Biochemistry
Purification
Elisa
Chromatography
Cell Biology
Formulation Development
Product Development
Clinical Development
Pharmaceuticals
Pharmaceutical Development
Languages:
Hindi
Telugu

Publications

Us Patents

Mitochondriotropic Phospholipid Vesicles

View page
US Patent:
20080095834, Apr 24, 2008
Filed:
Mar 2, 2006
Appl. No.:
11/885419
Inventors:
Volkmar Weissig - Nashua NH, US
Sarathi Boddapati - Boston MA, US
Robert Hanson - Newton MA, US
Vladimir Torchilin - Charlestown MA, US
International Classification:
A61K 9/127
A61K 31/70
A61P 43/00
A61K 38/00
US Classification:
424450000, 514002000, 514044000
Abstract:
Mitochondriotropic phospholipid vesicles, i.e., mitochondriotropic liposomes, that comprise a hydrophobized amphiphilic delocalized cation, such as those comprising, e.g., a triphenylphosphonium or a quinolinium moiety, incorporated into the phospholipid membrane of the vesicles, or liposomes, are disclosed. The hydrophobized portion of the amphiphilic delocalized cation, e.g., a fatty acid or other phospholipid derivative, is embedded in the phospholipid membrane of the liposome, and the amphiphilic portion of the cation is exposed on the surface of the liposome. Mitochondriotropic liposomes constitute a mitochondria-targeted drug delivery system, permitting the transport of a high payload of therapeutic water-soluble molecules in their native (i.e., active) state specifically and exclusively to mitochondria in living mammalian cells.

Vaccine Compositions Having Improved Stability And Immunogenicity

View page
US Patent:
20220387579, Dec 8, 2022
Filed:
May 23, 2022
Appl. No.:
17/750612
Inventors:
- Gaithersburg MD, US
Ye LIU - Clarksville MD, US
Jing-Hui TIAN - Germantown MD, US
Michael J. MASSARE - Mt. Airy MD, US
Sarathi BODDAPATI - Germantown MD, US
Erica SHANE - McLean VA, US
Cynthia OLIVER - Potomac MD, US
Gregory GLENN - Poolesville MD, US
International Classification:
A61K 39/155
A61K 39/12
A61K 9/00
A61K 9/16
C12N 7/00
Abstract:
Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Methods And Compositions For Treating Respiratory Disease

View page
US Patent:
20210137845, May 13, 2021
Filed:
Jul 24, 2018
Appl. No.:
16/629859
Inventors:
- Gaithersburg MD, US
Ye LIU - Clarksville MD, US
Jing-Hui TIAN - Germantown MD, US
Michael J. MASSARE - Mt. Airy MD, US
Sarathi BODDAPATI - Germantown MD, US
Gregory GLENN - Poolesville MD, US
Louis FRIES - Ellicott City MD, US
Iksung CHO - Potomac MD, US
International Classification:
A61K 9/51
A61K 39/155
A61P 31/14
A61P 11/00
Abstract:
Disclosed herein are methods and nanoparticles suitable for use in reducing exacerbations in COPD patients. The methods and compositions advantageously reduce the incidence of hospitalization in COPD patients that occurs in response to environmental insults such as exposure to or infection by RSV. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Vaccine Compositions Having Improved Stability And Immunogenicity

View page
US Patent:
20200101151, Apr 2, 2020
Filed:
Aug 20, 2019
Appl. No.:
16/545424
Inventors:
- Gaithersburg MD, US
Ye LIU - Clarksville MD, US
Jing-Hui TIAN - Germantown MD, US
Michael J. MASSARE - Mt. Airy MD, US
Sarathi BODDAPATI - Germantown MD, US
Erica SHANE - McLean VA, US
Cynthia OLIVER - Potomac MD, US
Gregory GLENN - Potomac MD, US
International Classification:
A61K 39/155
A61K 39/12
A61K 9/00
A61K 9/16
C12N 7/00
Abstract:
Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Vaccine Compositions Having Improved Stability And Immunogenicity

View page
US Patent:
20180133308, May 17, 2018
Filed:
Nov 21, 2017
Appl. No.:
15/819962
Inventors:
- Gaithersburg MD, US
Ye LIU - Clarksville MD, US
Jing-Hui TIAN - Germantown MD, US
Michael J. MASSARE - Mt. Airy MD, US
Sarathi BODDAPATI - Germantown MD, US
Erica SHANE - McLean VA, US
Cynthia OLIVER - Potomac MD, US
Gregory GLENN - Poolesville MD, US
Assignee:
Novavax, Inc. - Gaithersburg MD
International Classification:
A61K 39/155
A61K 9/16
C12N 7/00
A61K 9/00
A61K 39/00
Abstract:
Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Vaccine Compositions Containing Modified Zika Virus Antigens

View page
US Patent:
20170354729, Dec 14, 2017
Filed:
Mar 16, 2017
Appl. No.:
15/460775
Inventors:
- Gaithersburg MD, US
Jing-Hui TIAN - Gaithersburg MD, US
Gale SMITH - Gaithersburg MD, US
Michael J. MASSARE - Gaithersburg MD, US
Sarathi BODDAPATI - Gaithersburg MD, US
International Classification:
A61K 39/12
C12N 7/00
C07K 14/005
A61K 39/00
Abstract:
The present disclosure relates to vaccine compositions that comprise a Zika virus antigen and an adjuvant. The present disclosure also provides methods for inducing a protective immune response by administering the disclosed vaccine compositions in a subject in needs thereof. The present methods also comprise the binding of the Zika virus vaccine to Zika virus cellular receptor proteins.

Vaccine Compositions Having Improved Stability And Immunogenicity

View page
US Patent:
20170202948, Jul 20, 2017
Filed:
Sep 6, 2016
Appl. No.:
15/257436
Inventors:
- Gaithersburg MD, US
Ye Liu - Gaithersburg MD, US
Jing-Hui TIAN - Gaithersburg MD, US
Michael J. MASSARE - Gaithersburg MD, US
Sarathi BODDAPATI - Gaithersburg MD, US
Erica SHANE - Gaithersburg MD, US
Cynthia Oliver - Gaithersburg MD, US
Gregory GLENN - Gaithersburg MD, US
Assignee:
NOVAVAX, INC. - Gaithersburg MD
International Classification:
A61K 39/155
C12N 7/00
A61K 9/16
A61K 9/00
Abstract:
Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
Sarathi V Boddapati from Germantown, MD, age ~47 Get Report